Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib

Christine Saraceni, DO,* P. Mark Li, MD,* Justin F. Gainor, MD,† Gary A. Stopyra, MD,* and Eliot L. Friedman, MD*

CASE OF THE MONTH SUBMISSION
A 39-year-old woman nonsmoker presented in August 2007 with chest wall discomfort. Computed tomography (CT) revealed right upper lobe parenchymal and pleural abnormalities as well as mediastinal lymphadenopathy. Bronchoscopy and mediastinoscopy yielded a diagnosis of adenocarcinoma of the lung. No mutations in KRAS or epidermal growth factor receptor (EGFR) were identified.

She received four cycles of carboplatin, paclitaxel, and bevacizumab followed by maintenance bevacizumab and erlotinib. Her tissue was reanalyzed and an anaplastic lymphoma kinase (ALK) rearrangement was detected. After disease progression in March 2011, she began crizotinib 250mg orally twice daily on a phase II clinical trial (PROFILE 1005), ultimately achieving a complete remission. Initial magnetic resonance imaging (MRI) imaging of the brain was negative.

In July 2011, she developed pupil asymmetry. MRI of the brain revealed multiple, bilateral, cystic lesions without pathological enhancement. Lumbar puncture was unremarkable. Crizotinib was continued. She received Cyberknife therapy to a lesion in the thalamus and the other lesions were observed.

In September 2013, MRI of the brain demonstrated progression in size and number of the parenchymal cystic brain lesions (Fig. 1A, B). A CT scan of the chest and abdomen done at that time demonstrated disease stability. She underwent image-guided frontal craniotomy with biopsy of two cystic lesions. Pathology confirmed metastatic lung adenocarcinoma. The patient declined whole brain radiation therapy and began treatment with ceritinib (LDK387) in January 2014. An MRI of the brain performed in September 2014 demonstrated reduction of the previously noted brain metastases (Fig. 2). A chest-CT scan demonstrated continued stability of her systemic disease at that time.

DISCUSSION
The ALK rearrangement defines a distinct molecular subgroup within non–small-cell lung cancer. Its discovery has spurred the development of multiple molecular targeted...
agents, including crizotinib and ceritinib. Despite the therapeutic efficacy of crizotinib, patients will ultimately develop resistance to therapy, usually in the central nervous system. In addition, the cystic appearance of the brain metastases in our patient, as well as in two other case reports, describes a unique radiographic pattern in patients with ALK positivity.

This is the first case report with pathologic assessment of cystic central nervous system (CNS) lesions in patients taking crizotinib. Contrary to the first case report, which proposed a potential link between signet ring histology and cystic brain lesions, there were no signet ring cells in the CNS specimen in our case. This is also the first case report to explore the mechanism of resistance in CNS lesions resistant to crizotinib. Targeted next-generation sequencing, utilizing the T5a test sequencing 287 genes was performed (Foundation One, Foundation Medicine Inc., Cambridge, MA). No ALK resistance mutations were identified in the brain metastasis sample. No additional mutations imparting resistance were identified, raising the possibility of low CNS levels of crizotinib imparting resistance to the drug.

The next-generation ALK inhibitor ceritinib recently received accelerated approval for the treatment of ALK-positive patients resistant to and/or intolerant to crizotinib. In the phase I study of ceritinib, responses were observed in patients with brain metastases. Of note, the median progression-free survival after treatment with ceritinib was similar among patients with and without CNS metastases. Thus, the stability of the CNS lesions on ceritinib in our patient may reflect better CNS penetration.

Recently, several other next-generation ALK inhibitors with promising CNS activity have been developed. In a phase I/II study of the novel ALK inhibitor alectinib, objective responses in the CNS were observed in 11 of 21 (52%) patients with brain metastases. Cerebrospinal fluid sampling in five patients documented alectinib penetration into the cerebrospinal fluid compartment. Early studies of the next-generation ALK inhibitor AP26113 have also shown tumor regressions in 9 of 13 (69%) patients with untreated or progressing brain metastases. Moving forward, additional prospective data is needed to inform the duration of CNS responses in patients treated with second-generation ALK inhibitors and provide a better sense of the denominators of patients with CNS lesions treated with these agents.

REFERENCES